Molecular epidemiology of newly acquired hepatitis C infections in England 2008–2011: Genotype, phylogeny and mutation analysis
- 1 March 2015
- journal article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 64, 6-11
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Hepatitis BNursing Standard, 2014
- Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic ReviewAIDS and Behavior, 2013
- Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitorsJournal of Viral Hepatitis, 2011
- Assembly of infectious hepatitis C virus particlesTrends in Microbiology, 2011
- Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2010
- Planning for the healthcare burden of hepatitis C infection: Hepatitis C genotypes identified in England, 2002–2007Journal of Clinical Virology, 2010
- Natural Variability of NS3 Protease in Patients Infected with Genotype 4 Hepatitis C Virus (HCV): Implications for Antiviral Treatment Using Specifically Targeted Antiviral Therapy for HCVThe Journal of Infectious Diseases, 2009
- Diagnosis of acute hepatitis C virus infection and estimated incidence in low‐ and high‐risk English populationsJournal of Viral Hepatitis, 2008
- Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive SubjectsThe Journal of Infectious Diseases, 2008
- Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patientHepatology, 2008